Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Market Cap	50.00B -16.4%
Revenue (ttm)	8.04B +8.7%
Net Income	876.90M +129.9%
EPS	1.04 +135.5%
Shares Out	n/a
PE Ratio	57.02
Forward PE	52.07
Dividend	0.14 (0.36%)
Ex-Dividend Date	Jun 18, 2026

Volume	1,124,100
Open	41.58
Previous Close	40.92
Day's Range	39.30 - 41.58
52-Week Range	28.12 - 57.00
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, includ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 11,130
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3347

Financial Performance

In 2025, HKG:3347's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error